Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Urinary excretion of phenobarbital and its metabolitep-hydroxyphenobarbital in convulsing and non-convulsing patients

  • 74 Accesses

  • 1 Citations

Summary

As part of an investigation of phenobarbital (PB) pharmacokinetics in patients with status epilepticus (SE), urinary excretion of PB and its main metabolite, hydroxyphenobarbital (HPB), was studied in patients who had an episode of SE, as well as in non-convulsing ones. Eleven in-patients were studied: (group 1) five patients (4 M+1 F; 48±28 years old; 64±6 kg body weight; mean±SD) with convulsive status epilepticus, and (group 2) six patients (5 M+1 F; 37±13 years old; 71 ±15 kg body weight) with epilepsy, seizure-free at the moment of PB administration and without established anti-epileptic therapy. All subjects received a single intravenous dose of PB (15 mg/kg) at a rate of 100 mg/min. PB and HPB concentrations were measured by high performance liquid chromatography with UV detection at 220 nm in urine samples collected throughout 24 h. The comparison of pharmacokinetic parameters of urinary excretion of PB and HPB showed a statistically significant difference in the values of recovery of HPB and total barbiturate (higher values in the patients with SE) in 24 h urine. Differences in the excretion of PB between the two groups of patients — higher values in the patients who had had an episode of SE, and in urine flow — slightly elevated volumes in the same group, failed to reach statistical significance, probably due to the small number of participants in the study.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Shaner D.M., McCurdy S.A., Herring M.O., Gabor A.J. (1988): Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin. Neurology, 38: 202–207.

  2. 2.

    Donn S.M., Grasela T.M., Goldstein G.W. (1985): Safety of a higher loading dose in the term newborn. Pediatrics, 75: 1061–1064.

  3. 3.

    Whyte M.P., Dekaban A.S. (1977): Metabolic fate of phenobarbital: a quantatative study of p-hydroxyphenobarbital elimination in man. Drug Metab. Dispos., 5: 63–70.

  4. 4.

    Bhargava V.O., Soine W.H., Garrettson L.K. (1985): High-performance liquid chromatographic analysis of 1-(beta-d-glucopyranosil)phenobarbital in urine. J. Chromatogr. Biomed. Appl., 343: 219–223.

  5. 5.

    Butler T.C., Mahafee C., Wadell W.J. (1954): Phenobarbital: studies of elimination, accumulation, tolerance and dosage schedules. J. Pharmacol. Exp. Ther., 192: 425–235.

  6. 6.

    Alvin J., McHorse T., Hoyumpa A., Bush M.T., Schenker S.E. (1975): The effect of liver disease in man on the disposition of phenobarbital. J. Pharmacol. Exp. Ther., 192: 224–435.

  7. 7.

    Kapetanovic I.M., Kupferberg H.J., Porter R.J., Theodore W., Schulman E., Penry J.K. (1981): Mechanism of valproate-phenobarbital interaction in epileptic patients. Clin. Pharmacol. Ther., 29: 480–486.

  8. 8.

    Simon R.P. (1985): Physiologic consequences of status epilepticus. Epilepsia, 26 (Suppl. 1): S58-S66.

Download references

Author information

Correspondence to B. Brzakovic.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Brzakovic, B., Pokrajac, M., Dzoljic, E. et al. Urinary excretion of phenobarbital and its metabolitep-hydroxyphenobarbital in convulsing and non-convulsing patients. Eur. J. Drug Metab. Pharmacokinet. 24, 233–236 (1999). https://doi.org/10.1007/BF03190025

Download citation

Keywords

  • Phenobarbital
  • urinary excretion
  • status epilepticus